Diphenylarsinic acid (DPAA) was a major compound found in the arsenic poisoning incident that occurred in Kamisu, Ibaraki, Japan in 2003. People exposed to DPAA via contaminated well water suffered from several neurological disorders, including cerebellar symptoms. We previously reported that DPAA induces cellular activation in cultured rat cerebellar astrocytes, dose-dependent promotion of cell growth (low DPAA), cell death (high DPAA), and increased phosphorylation of mitogen-activated protein (MAP) kinases (p38MAPK, SAPK/JNK, and ERK1/2). Moreover, DPAA induces up-regulation of oxidative stress-counteracting proteins, activation of CREB phosphorylation, increased protein expression of c-Jun and cFos, and aberrant secretion of brain-active cytokines (MCP-1, adrenomedullin, FGF2, CXCL1, and IL-6). Here, we explored the role of MAP kinases in DPAA-induced activation of astrocytes using specific MAP kinase signaling inhibitors [SB203580 (p38MAPK), SP600125 (SAPK/JNK), SCH772984 (ERK1/2), and U0126 (MEK1/2, a kinase for ERK1/2)]. DPAA-induced activation of MAP kinases had little contribution to DPAA-induced cell growth and death. On the other hand, a power relationship among MAP kinases was also observed, in which p38MAPK suppressed DPAA-induced SAPK/JNK and ERK1/2 activation, whereas ERK1/2 and MEK1/2 facilitated p38MAPK and SAPK/JNK activation. In addition, SAPK/JNK had minimal effects on the activation of other MAP kinases. DPAA-induced activation of transcription factors and secretion of brain-active cytokines were submissively but intricately dominated by MAP kinases. Collectively, our results indicate that DPAAinduced activation of MAP kinases is neither a cell growth-promoting response nor a cytoprotective one but leads to transcriptional disruption and aberrant secretion of brain-active cytokines in cerebellar astrocytes.
Diphenylarsinic acid (DPAA) is a pentavalent organic arsenic compound that has been implicated in the arsenic poisoning incident that occurred in Kamisu, Ibaraki, Japan in 2003 (Ishii et al., 2004) . In this accident, arsenic chemicals detected in well water leaked from a nearly buried concrete block; concentrations of arsenic chemicals in the well water reached 4.5 mg As/L (60 mM), and DPAA was found to be the major contaminant (Ishizaki et al., 2005) . Local residents that domestically used the As-contaminated well water, including for drinking, suffered from neurological symptoms suggestive of cerebellar dysfunction, such as vertigo and coordination problems, myoclonus, somnipathy, visual disorders, and recent memory and cognitive disturbances (Ishii et al., 2004) . DPAA does not occur naturally, but it could be a raw material or degradation product associated with chemical weapons, such as diphenylcyanoarsine and diphenylchloroarsine, which can cause severe vomiting and sneezing. To date, most victims of the Kamisu poisoning incident have fortunately recovered after avoiding the use of the contaminated well water. However, some have been afflicted for a long time, and several children born during the accident suffered from developmental disorders (Ishii et al., 2004) . There have been several studies examining the toxicity of DPAA using hepatocellular carcinoma cells (Kita et al., 2007; Kita et al., 2009; Kita et al., 2012; Ochi et al., 2006) or mouse hepatocytes (Sumi et al., 2007) . As for the adverse effects of DPAA on central nervous system, we have previously reported DPAA-induced activation and traces of oxidative stress in cerebellar astrocytes in vivo and in vitro (Negishi et al., 2012) and abnormal behaviors, including reversible hyper locomotion and long-lasting learning and memory impairment, in male rats subchronically exposed to DPAA via drinking water [20 mg DPAA/L (76 mM)] (Negishi et al., 2013) . In addition, we recently demonstrated DPAAinduced activation of cultured rat cerebellar astrocytes (Negishi et al., 2016) . Interestingly, DPAA at 6.25 and 12.5 lM promoted cell growth at 96 h after exposure, whereas DPAA at 50 lM induced cell death in cultured astrocytes. Moreover, we reported increased phosphorylation of mitogen-activated protein (MAP) kinases (p38MAPK, SAPK/JNK, and ERK1/2), up-regulation of expression/phosphorylation of transcription factors [cAMP response element binding protein (CREB), c-Jun, and c-Fos], and increased secretion of brain-active cytokines (MCP-1, adrenomedullin, FGF2, CXCL1, and IL-6) as well as DPAA-induced up-regulation of the oxidative stress response [nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), Hsp70] (Negishi et al., 2016) . It is well known that the MAP kinases, p38MAPK, SAPK/JNK, and ERK1/2, have pivotal roles in numerous cellular functions, including cell proliferation, growth, survival, and cell death (Pandey et al., 2016) . These MAP kinases would control protein expression and phosphorylation of transcription factors, which might then promote the transcription of oxidative stress responsive factors such as Nrf2, HO-1, and Hsp70 as well as brain-active cytokines. It is relevant that, in DPAA-exposed astrocytes, the activation of MAP kinases contributes to various cellular responses including cell growth and cell death, and this MAP kinase/transcription factor/brainactive cytokine pathway has been considered to be a main functional target of DPAA, which may lead to the cerebellar toxicity due to DPAA. In cerebellar astrocytes, the adverse modulation of cellular functions by DPAA, such as aberrant secretion of brain-active cytokines, may cause extensive cerebellar dysfunction and be a primary cause of cerebellar symptoms by directly and indirectly affecting surrounding neurons, microglia, vascular cells, and astrocytes themselves. Therefore, in the present study, we investigated the role of DPAA-induced MAP kinase activation in DPAA-induced astrocyte activation, including the promotion of cell growth, cytotoxicity, induction of oxidative stress-counteracting proteins, activation of transcription factors, and secretion of brain-active cytokines. For this purpose, we used the specific MAP kinases inhibitors, SB203580, SP600125, and SCH772984, which are selective ATP-competitive inhibitors of p38MAPK, SAPK/JNK, and ERK1/2, respectively. In addition, the role of MEK1/2, a specific kinase for ERK1/2 (Lu and Xu, 2006) , was investigated using the non-ATP competitive MEK1/2 inhibitor, U0126.
We noticed here that DPAA itself is not an abandoned chemical warfare agent causing nausea and vomiting but is likely a raw material of chemical weapons. More than a decade has passed since the Kamisu incident; however, the biological impacts of DPAA on human health are not well understood. Therefore, in the present study, we investigated the underlying mechanisms of cerebellar toxicity associated with DPAA exposure for developing preventive and therapeutic strategies against DPAA intoxication, which may occur in the future.
MATERIALS AND METHODS

Chemicals
DPAA (> 99%) was purchased from Tri Chemical Laboratories (Yamanashi, Japan). The p38MAPK and SAPK/JNK inhibitors, SB203580 (SB), and SP600125 (SP), respectively, were purchased from Tocris Bioscience (Minnesota, USA). The ERK1/2 inhibitor, SCH772984, was purchased from ChemieTek (Indiana, USA) and the MEK1/2 inhibitor, U0126, was purchased from SigmaAldrich (Missouri, USA).
Animals
Pregnant Wistar rats were purchased from Japan SLC (Shizuoka, Japan) and maintained under controlled conditions. All animal experiments were approved by the Animal Experimentation Committee of Aoyama Gakuin University and performed under veterinary supervision.
Cell Culture
Cultured rat cerebellar astrocytes were prepared as previously described (Negishi et al., 2016; Oyanagi et al., 2015) . Briefly, the cerebella of Wistar rats at postnatal day 2 were dissected under sterile conditions and dispersed by trypsin (Invitrogen, California, USA). Dissociated cerebellar cells were then cultured in DMEM/F-12 containing 10% fetal bovine serum for 7-10 days. In these cultures, astrocytes were dominant among cerebellar cells including neurons and microglia, because of their high proliferation potency. To enhance astrocyte purity, cells were subsequently passaged 5-7 times to obtain sufficient numbers of astrocytes, which were frozen and preserved until use. All experiments used cultured astrocytes that had undergone 8-11 passages. For exposure experiments, astrocytes were seeded at 500 cells/mm 2 and cultured in serum-containing medium for 48 h. After this initial period, the cells were cultured in serumfree medium [DMEM/F-12 with insulin-transferrin-selenite supplement (Invitrogen)] for another 48 h. All test chemicals were first dissolved in dimethyl sulfoxide (Sigma-Aldrich) as stock solutions and then added to the serum-free medium. Astrocytes were exposed to each chemical at the indicated concentrations by bath-application of chemical-containing serum-free medium for 96 h. In each experiment, the control cells were exposed to the vehicle (dimethyl sulfoxide) at appropriate concentrations.
Cell Viability and Cell Death in Cultured Cells
Cell viability of cultured astrocytes exposed to DPAA or other chemicals was quantified using the CellTiter-Blue TM Cell
Viability Assay (Promega, Wisconsin, USA). The cytotoxicity of DPAA or other chemicals was measured using the CytoToxFluor TM Cytotoxicity Assay (Promega), which measures the protease activity of a distinct protease released from dead cells that have lost membrane integrity.
Live/Dead Cell Staining
Live/dead cell staining was performed as described previously (Negishi et al., 2016) . Briefly, cells exposed to DPAA were incubated simultaneously with the membrane impermeable dye, propidium iodide (PI; Sigma-Aldrich), and a membrane permeable dye, Hoechst 33342 (Sigma-Aldrich). In this system, the nuclei of living cells are stained only with Hoechst, while those of dead cells that have lost membrane integrity are stained with both Hoechst and PI.
Western Blotting
Protein expression and phosphorylation levels in cultured rat cerebellar astrocytes were evaluated using Western blotting, detailed methods of which are shown in our previous study (Negishi et al., 2016 ImmunoResearch) were appropriately diluted in the blocking buffer or Can Get Signal Solution 2 (Toyobo). Immobilon Western Chemiluminescence HRP Substrate (Millipore) was used for the visualization of immunoreactive molecules, and recorded using an EZ-Capture system (Atto, Japan).
Enzyme Immunoassay
Commercial EIA kits for each peptide were as follows: MCP-1 (CCL2) EIA Kit (Immuno-Biological Laboratories, Gumma, Japan) for MCP-1 (CCL2); adrenomedullin (1-50) (rat), EIA Kit (Phoenix Pharmaceuticals) for adrenomedullin; human FGF basic Quantikine ELISA Kit (R&D Systems); Cxcl1 (Rat) ELISA Kit (Abnova, Taipei City, Taiwan) and Rat CXCL1/CINC-1 Quantikine ELISA Kit (R&D Systems) for CXCL1; and Rat IL-6 Quantikine ELISA Kit for IL-6 (R&D Systems). The culture medium after exposure to DPAA or other compounds was collected and centrifuged at 800 Â g for 10 min and the supernatant was stored at À20 C until use. The culture medium sample was subjected to EIA directly or after concentration by vacuum centrifugation. EIA was performed according to the product manual for each EIA kit.
Arsenic Level
The measurement of arsenic levels in cultured astrocytes and culture medium was performed according to procedures described in previous studies (Kobayashi et al., 2008; Kobayashi and Hirano, 2013) . Cultured astrocytes were exposed to DPAA at 10 lM for 96 h. Astrocytes were then collected after washing and homogenized in distilled water. Cell aliquots were used for measurements of protein concentration. The protein concentration of cell homogenates was adjusted to 1.0 lg/ll with distilled water, and samples were frozen at À80 C until use. The culture medium was centrifuged to remove debris and supernatant medium samples were frozen at À80 C until use. Cell homogenates and cultured medium were wet-ashed with nitric acid and hydrogen peroxide 3:1 (v:v). The samples were diluted with water, and total arsenic concentrations were measured by inductively coupled plasma mass spectrometry (ICP-MS). Arsenic levels in cell homogenates and cultured medium were calculated as lg/mg protein and mg/ml (or lM), respectively. concentration of peptides released into the culture medium was analyzed by two-way ANOVA followed by Dunnett's tests for multiple comparisons. For all statistical analyses, the a-value was set at 0.05. Detailed results of statistical analyses are shown in Supplementary Data (Supplementary Tables 2-17) .
Statistical Analysis
RESULTS
Effects of DPAA on Cell Proliferation, Cell Death, and Morphological Changes
In cultured rat cerebellar astrocytes, exposure to DPAA ( Figure  1A ), a pentavalent arsenic, caused statistically significant (P < 0.05) increases in cell viability based on cellular metabolic activity at a particular dose range of 3.13-25 lM after 96-h exposure ( Figure 1B , left panel). However, exposure to DPAA at higher doses (50 and 100 lM) for 96 h induced significant increases (P < 0.05) in cell death based on protease activity leaking from dead cells ( Figure 1B , right panel). There appears to be an inconsistency when astrocytes were exposed to DPAA at 50 lM or more for 96 h, because there was an apparent decrease (less than 50%) in cell viability but only a slight increase (less than 25%) in the cytotoxicity index based on protease activity. Thus, some caution should be exercised in the interpretation of these percentages as absolute values; protease activity in the culture medium of the CytoTox-Fluor assay inevitably decreases in a time-dependent manner. It appears that the percent of the lysed sample itself would be less meaningful; nevertheless, these values are useful to assess the dose-response cytotoxicity of DPAA for the same exposure time. Phase contrast microscopic images ( Figure 1C ) showed morphological changes, including cell rounding, in cultured rat cerebellar astrocytes exposed to DPAA at 6.25 lM or more for 96 h [enlarged photographs are presented in Supplementary Data (Supplementary Figure 1A) ]. Live/dead staining also implied that exposure to DPAA at a certain dose range around 10 lM induced cell growth but at higher doses (12.5 lM or more) caused significant cell death (Supplementary Figure 1B) .
Arsenic Level in Cellular Components
Arsenic level in cultured astrocytes exposed to DPAA at 10 lM for 96 h was 131.2 6 22.3 ng/mg cellular protein (mean 6 SD, n ¼ 4). Arsenic level in three of four samples derived from control astrocytes was under detection limit and was 2.0 ng/mg cellular protein in the remaining one. Arsenic level in the culture medium in which astrocytes were exposed to DPAA at 10 lM for 96 h was 633 and 645 ng/ml (n ¼ 2), which corresponded to 8.45 and 8.62 lM, respectively. The background level of arsenicals in the serum-free medium was <10 ng/ml.
Role of the p38MAPK Signaling Pathway in DPAAInduced Astrocyte Activation SB203580, a selective ATP-competitive inhibitor of p38MAPK (Cuenda et al., 1995) , was used to investigate the role of the p38MAPK signaling pathway in DPAA-induced astrocyte activation ( Figure 2A) . First, the effects of SB203580 on cell viability in DPAA-exposed astrocytes were evaluated using an assay based on cellular metabolic activity ( Figure 2B ). We found that SB203580 slightly suppressed cell viability at 10 lM or higher, which was independent of exposure to DPAA. In other words, there was little DPAA-dependent alteration in sensitivity to SB203580. SB203580 neither suppressed nor promoted 10 lM DPAA-induced cell growth, and it neither enhanced nor ameliorated 50 lM DPAA-induced cytotoxicity. Second, the protein expression of DPAA-responsive factors identified above was analyzed. Representative immunoblot images of these proteins are shown in Supplementary Data (Supplementary Figure  2) . SB203580 did not affect DPAA-induced increased expression of Nrf2 and Hsp70; however, it slightly but significantly (P < 0.05) suppressed that of HO-1 in a dose-dependent manner ( Figure  2C ). SB203580 increased the phosphorylation and total protein expression of p38MAPK, irrespective of exposure to DPAA ( Figure 2D ), indicating the presence of certain feedback loop inhibition. In addition, SB203580 increased the phosphorylation of SAPK/JNK and ERK1/2 but not total protein expression ( Figure  2D ). As for transcription factors, SB203580 significantly (P < 0.05) suppressed DPAA-induced increase in CREB phosphorylation, as well as the basal phosphorylation level in the absence of DPAA ( Figure 2D ). On the other hand, SB203580 significantly (P < 0.05) accelerated DPAA-induced increases in the protein expression and phosphorylation of c-Jun and c-Fos ( Figure 2D ). Finally, SB203580 significantly (P < 0.05) suppressed DPAAinduced secretion of MCP-1, adrenomedullin, CXCL1, and IL-6, while it enhanced that of FGF2 ( Figure 2F ). In the DPAA-free control condition, SB203580 alone significantly (P < 0.05) induced the secretion of adrenomedullin and FGF2 but suppressed that of CXCL1 ( Figure 2F ).
Role of the SAPK/JNK Signaling Pathway in DPAAInduced Astrocyte Activation
The role of SAPK/JNK in DPAA-induced astrocyte activation was investigated using inhibition of its kinase activity by SP600125, a selective ATP-competitive SAPK/JNK inhibitor (Han et al., 2001 ) ( Figure 3A ). SP600125 significantly (P < 0.05) suppressed cell viability in a dose-dependent manner ( Figure 3B ). SP600125 neither suppressed nor promoted 10 lM DPAA-induced cell growth, and it neither enhanced nor ameliorated 50 lM DPAA-induced cytotoxicity. SP600125 significantly (P < 0.05) suppressed DPAAinduced increases in the protein expression of Nrf2, HO-1, and Hsp70 ( Figure 3C ). SP600125 minimally affected DPAA-induced increases in the phosphorylation and expression of MAP kinases, with the exception of a significant (P < 0.05) but modest suppression of ERK1/2 phosphorylation ( Figure 3D ). SP600125 also significantly (P < 0.05) suppressed DPAA-induced increases in the phosphorylation of CREB, c-Jun, and c-Fos, as well as the protein expression of c-Fos ( Figure 3E ). Representative immunoblot images of these proteins are shown in Supplementary Data (Supplementary Figure 3) . In addition, SP600125 significantly (P < 0.05) interrupted the DPAA-induced secretion of MCP-1, FGF2, CXCL1, and IL-6 but not that of adrenomedullin ( Figure 3F ).
Role of the ERK1/2 Signaling Pathway in DPAA-Induced Astrocyte Activation
Cultured astrocytes were treated with DPAA and/or SCH772984, a newly available ATP-competitive ERK1/2 inhibitor (Morris et al., 2013) , to probe a possible role of ERK1/2 activity in DPAAinduced astrocyte activation ( Figure 4A ). SCH772984 induced a slight (< 20%) but significant (P < 0.05) reduction in cell viability without clear dose-dependent manner ( Figure 4B ). SCH772984 even at the highest dose (10 lM) decreased cell viability by only 12%, irrespective of the dose of DPAA. Like other MAP kinase inhibitors, SCH772984 also showed no effect on either 10 lM DPAA-induced cell growth or 50 lM DPAA-induced cytotoxicity. SCH772984 partially, but significantly (P < 0.05), suppressed DPAA-induced increases in Nrf2 and Hsp70 protein expression, but not that of HO-1 ( Figure 4C ). SCH772984 also significantly (P < 0.05) reduced DPAA-induced increases in the phosphorylation of p38MAPK, SAPK/JNK, and ERK1/2 ( Figure 4D ). SCH772984 in control astrocytes induced a significant (P < 0.05) increase in ERK1/2 phosphorylation. Similarly, this inhibitor significantly (P < 0.05) reduced SAPK/JNK and ERK1/2 protein expression, irrespective of the presence of DPAA. SCH772984 also significantly (P < 0.05) suppressed the phosphorylation and protein expression of CREB both in the absence and presence of DPAA, and suppressed DPAA-induced phosphorylation and protein expression of c-Jun and c-Fos ( Figure 4E ). Representative immunoblot images of these proteins are shown in Supplementary Data (Supplementary Figure 4) . Furthermore, DPAA induced a significant (P < 0.05) increase in the phosphorylation and protein expression of MEK1/2 (Supplementary Figure 4 in Supplementary Data). As expected, SCH772984, irrespective of exposure to DPAA, significantly (P < 0.05) induced increase in phosphorylation of MEK1/2. SCH772984 also affected DPAA-induced secretion of brain-active cytokines ( Figure 4F ); SCH772984 significantly (P < 0.05) suppressed DPAA-induced secretion of MCP-1, adrenomedullin, and CXCL1, while it enhanced that of FGF2 and IL-6. Without exposure to DPAA, SCH772984 significantly (P < 0.05) inhibited the secretion of adrenomedullin and induced the secretion of FGF2.
Role of the MEK1/2 Signaling Pathway in DPAA-Induced Astrocyte Activation
In astrocytes exposed to DPAA, MEK1/2, the upstream MAPKK of ERK1/2, was inhibited by U0126, a major non-competitive MEK1/ 2 inhibitor ( Figure 5A ). In addition, U0126 intricately affected cell viability. When a wide dose range (0, 2.5, 5, 10, and 20 lM) of U0126 was tested first (Supplementary Figure 5 in Supplementary Data), U0126 at 20 lM remarkably decreased cell viability, irrespective of DPAA dose. In contrast, U0126 at 10 lM significantly (P < 0.05) increased cell viability in the absence of DPAA, while U0126 at 5 lM showed no effect. Thus, a narrow range of U0126 was determined (0, 10.2, 12.8, 16, 20 lM) and cell viability assays were performed ( Figure 5B ). U0126 at 16 and 20 lM induced significant (P < 0.05) loss of cell viability, irrespective of DPAA dose. However, U0126 at 10.2 or 12.8 lM significantly (P < 0.05) increased cell viability in the absence of DPAA. In the presence of 10 lM DPAA, U0126 at 10.2 lM did not affect cell viability, but 12.8 lM U0126 significantly (P < 0.05) suppressed DPAA-induced increases in cell viability to levels comparable to those observed in control astrocytes free from both DPAA and U0126 ( Figure 5B ). Moreover, U0126 at 10.2 and 12. 8 lM significantly (P < 0.05) decreased cell viability in the presence of high-dose DPAA (50 lM). Consequently, U0126 at the doses of 10.2 or 12.8 lM was applied for the following experiments. U0126 minimally affected DPAA-induced increases in the phosphorylation of MEK1/2, although it suppressed MEK1/2 protein expression (Supplementary Figure 5 in Supplementary Data). U0126 at 10.2 and 12.8 lM significantly (P < 0.05) suppressed DPAA-induced increases in Nrf2, and it induced significant decreases even without DPAA ( Figure 5C ). U0126 at 10.2 and 12.8 lM significantly (P < 0.05) suppressed DPAA-induced increases in HO-1 protein expression ( Figure 5C ), while U0126 only at the high dose (12.8 lM) suppressed DPAA-induced increases in Hsp70 expression. U0126 at 10.2 and 12.8 lM significantly (P < 0.05) suppressed DPAA-induced phosphorylation of p38MAPK and SAPK/JNK ( Figure 5D ). Unexpectedly, U0126 at 10. 2 lM significantly (P < 0.05) facilitated DPAA-induced phosphorylation of ERK1/2, while U0126 at 12.8 lM significantly (P < 0.05) suppressed phosphorylation of ERK1/2 (27% decrease vs DPAA at 10lM without U0126) ( Figure 5D ). U0126 showed a tendency (not statistically significant) to decrease DPAAinduced CREB phosphorylation ( Figure 5E ). On the other hand, U0126 at 10.2 and 12.8 lM significantly (P < 0.05) suppressed DPAA-induced phosphorylation and expression of c-Jun and cFos ( Figure 5E ). Representative immunoblot images of these proteins are shown in Supplementary Data (Supplementary Figure  5) . In addition, U0126 at 10.2 and 12.8 lM significantly (P < 0.05) suppressed DPAA-induced secretion of MCP-1, CXCL1, and IL-6 ( Figure 5F ). U0126 at 12.8 lM significantly (P < 0.05) and remarkably (12-fold increase) facilitated DPAA-induced secretion of FGF2 ( Figure 5F ).
DISCUSSION
In the present study, we investigated the role of three major MAP kinases, p38MAPK, SAPK/JNK, and ERK1/2, using selective inhibitors for each MAP kinase to determine a key signaling cascade in DPAA-induced activation of cultured rat cerebellar astrocytes.
We focused on the adverse effects of DPAA, particularly in astrocytes of the cerebellum, because our previous findings indicated that DPAA-induced cellular events occur entirely in rat cerebellar astrocytes (Negishi et al., 2012) . In addition, we have also previously reported that DPAA exposure in Wistar rats at 20 mg/l in drinking water from birth to 12 weeks of age induced a transient increase in exploratory behavior, longlasting impairment in learning behavior, and decreased cerebellar glutathione concentration (Negishi et al., 2013) . However, except for the decreased expression of proteins required for glutamatergic neurotransmission, little neuropathological evidence of DPAA exposure exists (Negishi et al., 2013) . In addition, clear pathological evidence in cerebellar neurons (Purkinje cells and granule cells) in rats exposed to even a higher dose of DPAA (100 mg/l in drinking water) was not found. Conversely, the oral administration of DPAA (5 mg/kg/day for 5 weeks) in mice has been reported to induce oxidative and nitrosative stress in Purkinje cells (Kato et al., 2007) . Thus, further investigation of the functional and/or morphological properties of DPAA-exposed cerebellar neurons including Purkinje cells, considering neuronastrocyte interactions, is warranted for further understanding DPAA-induced cerebellar symptoms.
Cell viability assays indicated that DPAA promoted cell growth at a certain dose range, specifically 3.13-25 lM, while DPAA at a higher dose range of 50-100 lM induced cell death after 96 h of exposure. Exposure to DPAA at 6.25-25 lM for 96 h induced morphological changes in cultured rat astrocytes, including transition from flat and confluent cells to round and swollen cells. With regard to the arsenic level in the present study, astrocytes exposed to 10 mM DPAA for 96 h contained 130 ng As/mg protein. Given that 20% of the cell content was protein and the bulk density of astrocytes was 1.05, a rough calculation indicates that astrocytes exposed to 10 mM DPAA contain arsenic at 364 mM. We have no intention to make further interpretation of this hypothetical value ignoring in vitro specific conditions. Collectively, considerable long-term DPAA exposure and the expected cellular persistence of DPAA may explain the sustained symptoms in the Kamisu accident and suggests the importance of developing treatments to not only accelerate the excretion of DPAA but also provide rapid relief from symptoms.
DPAA may have growth-promoting activity and be simultaneously cytotoxic depending on the dose. It may also further induce the phosphorylation of MAP kinases, upregulation of transcription factors, and release of brain-active cytokines in rat cerebellar astrocytes (Negishi et al., 2016) . However, the direct molecular mechanism of DPAA in cerebellar astrocytes remains to be completely understood. A series of previous studies (Kita et al., 2007; Kita et al., 2009; Kita et al., 2012) have attempted to reveal the molecular toxicity mechanisms of DPAA in hepatocellular carcinoma cells (HepG2 cells), in which DPAA reduces glutaminase C, which generates glutamate from glutamine. Further investigation of glutaminase C in DPAA-exposed astrocytes appears to be important, although glutaminase C enzyme is abundantly expressed in glutamatergic neurons for neurotransmission and much less in astrocytes. A previous study reported that glutathione-conjugated DPAA containing trivalent arsenic was highly toxic (1000-fold of DPAA) in HepG2 cells and that it changed to protein bound As. Although little is known regarding DPAA biotransformation in the human body, orally administered DPAA in rats is excreted in urine and feces as the unchanged DPAA or in bile as DPAA or glutathione-conjugated DPAA . These findings indicate that glutathione-conjugated DPAA may be produced either enzymatically (by glutathione S-transferase) or nonenzymatically in the liver, a glutathione-rich organ. Interestingly, astrocytes play a key role in glutathione metabolism in the brain (Dringen, 2000) . Thus, the speciation of arsenicals in DPAA-exposed astrocytes and culture medium is very interesting and should be included in further study.
We assessed the cytotoxic, growth-suppressive, and/or growth-promoting effects of MAP kinase inhibitors (SB203580, SP600125, SCH772984, and U0126 for inhibitions of p38MAPK, SAPK/JNK, ERK1/2, and MEK1/2, respectively) on cell viability in astrocytes exposed to DPAA at 0, 10, or 50 lM as control, proliferative, or cytotoxic doses, respectively. There was little apparent alteration in susceptibility/vulnerability to the three MAP kinase inhibitors both when DPAA at 10 lM promoted the growth of astrocytes and when DPAA at 50 lM exhibited cytotoxicity, suggesting that MAP kinases have little relationship with both DPAA-induced cell growth at 10 lM and cell death at 50 lM. This appears to be an unexpected result because MAP kinases are well known as cell growth-promoting factors during development and cytoprotective ones counteracting various stresses including oxidative stress during pathological conditions. Pathway other than MAP kinase cascades induced by DPAA exposure should be considered for investigating DPAAinduced cell growth/death (Figure 6 ). On the other hand, unlike direct MAP kinase inhibitors, U0126, an inhibitor of MEK1/2, showed quite unpredictable dose responsibility in the cell viability of DPAA-exposed astrocytes. In control astrocytes, excessive inhibition of the constitutive activation of MEK1/2 induced cell death, but moderate suppression led to cell proliferation. On the other hand, in activated astrocytes exposed to DPAA at 10 lM, a proliferative effect of U0126 that was observed in control cells may be concealed. In addition, it appears that exposure to DPAA at 50 lM increased the vulnerability of astrocytes to U0126, which suggests that MEK1/2 might play a protective role in the cell death of astrocytes exposed to high cytotoxic dose of DPAA. On the contrary, in the absence of DPAA (control), constitutive MEK1/2 activity might suppress cell growth, although there was a discrepancy between the effect of inhibition of MEK1/2 and ERK1/2 activities. Entirely different dose-response patterns between U0126 and SCH772984 on cell viability in control cells make it actually impossible to speculate a simple role of ERK1/2 for cell growth/death. Indeed, all inhibitors selected and tested in the present study were more or less cytotoxic. It is reasonable to assume that long term inhibition of these kinases (up to 96 h) causes cell death. Subsequently, although the doses of each inhibitor used in the following experiments showed a slight adverse effect on cell viability, in the present study, we tried to uncover the intracellular molecular mechanisms of DPAA-induced activation of astrocytes, with particular focus on MAP kinases activation, which should be regarded as the first priority.
DPAA-induced HO-1 expression was significantly reversed by inhibition of p38MAPK, SAPK/JNK, and MEK1/2, and slightly reversed by ERK1/2 inhibition. DPAA-induced increase in Nrf2 expression was suppressed by inhibition of SAPK/JNK, ERK1/2, and MEK1/2, but not by inhibition of p38MAPK. Similarly, DPAAinduced Hsp70 expression was significantly suppressed by inhibition of SAPK/JNK, ERK1/2, and MEK1/2, but not by inhibition of p38MAPK. These results suggest an intimate relationship between the activity of MAP kinases and the expression of HO-1 and Hsp70. Nrf2 is a well-known transcription factor that directly regulates the transcription of HO-1 (Chen et al., 2005) . However, it was difficult to conclude that the protein expression levels of HO-1 entirely followed those of Nrf2 in some cases. MAP kinase-induced nuclear translocation and phosphorylation of Nrf2 should be investigated by using extracts of nuclear protein to more precisely determine the relationship between Nrf2 and HO-1. Nonetheless, DPAA-induced increases in Nrf2, HO-1, and Hsp70 expression appear to be a cytoprotective reaction against oxidative stress, which raises the possibility that DPAA-induced MAP kinases phosphorylation (activation) is a countermeasure (self-defense) against oxidative stress and other possible adverse effects caused by DPAA.
DPAA markedly and simultaneously increased the phosphorylation of p38MAPK, SAPK/JNK, and ERK1/2 (and MEK1/2) in astrocytes. Every MAP kinase (and MEK1/2) would be phosphorylated by each specific upstream kinase(s) like the MEK1/2-ERK1/2 cascade, which stimulates its kinase activity for phosphorylating downstream substrates. To our knowledge, there are few agents that are capable of inducing the phosphorylation of these three MAP kinases simultaneously and strikingly (see ERK1/2 band-pattern change due to DPAA) in a cell population. Pharmacological assessment of the four inhibitors elucidated the following crosstalk between MAP kinases in DPAA-exposed astrocytes ( Figure 6 ): in the presence of DPAA, p38MAPK suppressed DPAA-induced activation of SAPK/JNK and ERK1/2, SAPK/JNK had little effect on other kinase activation, and ERK1/ 2 and its upstream kinase MEK1/2 facilitated the activation of p38MAPK and SAPK/JNK. However, there were several unexpected reaction patterns in the phosphorylation of ERK1/2 when ERK1/2 itself or upstream MEK1/2 was inhibited. Inhibition of ERK1/2 activity by SCH772984 decreased the phosphorylation of ERK1/2 despite the up-regulation of MEK1/2 activity, and inhibition of ERK1/2 activation by U0126 at a lower dose (10.2 lM) increased the phosphorylation of ERK1/2 but U0126 at a higher dose (12.8 lM) decreased ERK1/2 phosphorylation. The former unexpected reaction may be explained by the autophosphorylation of residues in the activation loop of ERK1/2 by ERK1/2, which can be inhibited by SCH772984 (Morris et al., 2013) . DPAA may induce ERK1/2 autophosphorylation, and SCH772984 effectively and perfectly inhibited DPAA-induced ERK1/2 autophosphorylation, which might explain the reason underlying the little dose dependency of SCH772984 on ERK1/2 phosphorylation; DPAA-induced ERK1/2 autophosphorylation might account for only a half of the whole DPAA-induced ERK1/2 phosphorylation. On the other hand, the alteration of the phosphorylation levels of ERK1/2 and MEK1/2 by SCH772984 in control astrocytes was reasonable, in which there would be a negative-feedback in the MEK1/2-ERK1/2 signaling pathway with inhibition of ERK1/2 activity resulting in the over activation of MEK1/2. In the latter case, inhibition of MEK1/2 also induced another unexpected alteration in DPAA-induced increases in phosphorylated ERK1/2. Usually, inhibition of MEK1/2 by U0126 results in a decrease in the phosphorylation of ERK1/2. Indeed, in control astrocytes, U0126 seemed to wipe out phosphorylated ERK1/2. In the presence of DPAA, although the phosphorylation level of ERK1/2 was decreased some by U0126 at 12.8 lM, it was increased by U0126 at 10.2 lM. The small decrease by U0126 at 12.8 lM in the phosphorylation level of ERK1/2 may not be due to the blocking of MEK1/2-ERK1/2 signaling pathway, but may be the result of a decrease in total ERK1/2 protein levels that occurred simultaneously by U0126. Similarly, decrease in DPAAinduced phosphorylation of p38MAPK and SAPK/JNK might be due to decrease in the total protein expression level by U0126. In addition, inhibition of MEK1/2 by U0126 at 10.2 lM failed to decrease the phosphorylation levels of ERK1/2, which suggests that the DPAA-induced increase in ERK1/2 phosphorylation is actually independent from MEK1/2 activity. In short, proper efficacy of DPAA on ERK1/2 may be inhibition of ERK1/2 dephosphorylation by protein phosphatases as well as induction of ERK1/2 autophosphorylation. The particular crosstalk between these MAP kinase pathways might be limited only to astrocytes exposed to DPAA. The actual outcome of the interaction between MAP kinases would undoubtedly be highly dependent on the cellular context. Cell type specificities against DPAA should be further investigated and may suggest the necessary condition(s) of DPAA-induced cellular activation. In addition, further investigation of the role of MAP kinases in astrocytes activated by DPAA (e.g., adding a drug directly into DPAA-containing medium or exchanging DPAA-containing culture medium for drugcontaining DPAA-free medium at 96 h after DPAA exposure) would contribute to search for potential therapeutic or prophylactic agents against DPAA intoxication.
Inhibition of MAP kinases similarly suppressed DPAAinduced increases in the phosphorylation of CREB, which indicates that the level of phosphorylated CREB might be under control of all three MAP kinases examined. DPAA also induced marked increases in the protein expression of c-Jun and c-Fos, two major transcription factors, and their phosphorylation. In the presence of DPAA, there was a strong correlation/proportional connection between the level of expression and that of phosphorylation in c-Jun and c-Fos, with the exception of SAPK/ JNK (c-Jun N-terminal kinase) inhibition where c-Jun phosphorylation levels decreased but protein expression levels did not change. The present results indicate that DPAA-induced increases in the phosphorylation of ERK1/2 may be responsible for the protein expression of c-Jun and c-Fos, and that of SAPK/JNK for c-Fos expression. On the other hand, in the presence of DPAA, p38MAPK may work as a suppressor of SAPK/JNK and ERK1/2 activity, as discussed above, with consequent suppression of DPAA-induced expression of c-Jun and c-Fos, which additionally supports a strong causal relationship between MAP kinase activation and the expression of c-Jun and c-Fos. DPAA-exposed astrocytes secreted the brain-active cytokines, MCP-1, adrenomedullin, FGF2, CXCL1, and IL-6, into culture medium. The possible role of these cytokines in DPAAexposed brain tissues including cerebellum was reviewed in detail in our previous studies (Negishi et al., 2012; Negishi et al., 2016) . We suspect that the secretion of brain-active cytokines from DPAA-exposed astrocytes may affect various cellular functions in neurons, microglia, and vascular cells, as well as the astrocytes themselves, consequently leading to cerebellar dysregulation. In the present study, the role of the MAP kinase signaling pathway in the secretion of these brain-active cytokines was investigated. However, while these brain-active cytokines were similarly secreted from DPAA-exposed astrocytes, they would be under different regulatory mechanisms. Nevertheless, DPAA-induced secretion of MCP-1 and CXCL1 were similarly suppressed by inhibition of MAP kinases. Interestingly, DPAAinduced FGF2 secretion was facilitated by the inhibition of p38MAPK, ERK1/2, and MEK1/2, but it was suppressed by the inhibition of SAPK/JNK. We could not definitively decipher the secretory regulation that was distorted by DPAA. Further investigation regarding the merits and demerits of DPAAinduced over-secretion of these brain-active cytokines in in vivo brain as well as in vitro cultured cell would be required.
In the present study, we explored the role of MAP kinases in astrocytes exposed to DPAA. Complicated regulatory interactions among MAP kinases activated by DPAA were found (Figure 6 ), which makes it substantially difficult to infer any specific pathway forcedly disrupted by DPAA. On the other hand, we must inquire into the biological significance of inclusive and indiscriminate activation of MAP kinase pathways by DPAA. Based on the present results, DPAA-induced activation of ERK1/ 2 among three MAP kinases may be a possible target for preventive/therapeutic intervention. When it comes to the possible molecular mechanisms of DPAA-induced activation of astrocytes, to date, reactive oxygen species (ROS) indirectly induced by DPAA have been suspected to be a key factor. However, as far as we know, there is little evidence that oxidative stress by the production of ROS could induce the activation of all the major MAP kinases simultaneously. In other words, it seems that DPAA-induced hyperactivation of the MAP kinase signaling pathway should not be supposed as a pathway responsive to ROS generated by DPAA but, rather, it may be the result of a dysfunction of inactivation/dephosphorylation of MAP kinases by phosphatases (Caunt and Keyse, 2013; Junttila et al., 2008) . Further studies focusing on the dynamics of phosphatases such as the dual-specificity MAP kinase phosphatases (DUSPs) in DPAA-exposed astrocytes are warranted. In addition, the direct molecular target(s) of DPAA and its chemical form(s) should be determined to elucidate the origin of DPAA-induced dysregulation of MAP kinases. A further comprehensive understanding of the cellular mechanisms induced by DPAA would provide useful information for developing preventive and therapeutic strategies against a possible DPAA intoxication similar to the Kamisu accident.
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